


[図1]



pHIgH5zeo (7.9kb)
NotI:7197
pUC-ori
NotI:753
AscI:918
syn.poly(A)
TOPO1-promoter
CMV enhancer
hE2F1a promoter
TOP1MARII+
Intron
HTLV R-U5'
bAct/bGlo hybrid Intron
NheI:1740
EcoRI:2318
(Esp3I):2388
VH
HindIII:5568
zeocin-R
TOPO1 poly(A)
SV40 poly(A)
WPRE
(Esp3I):2791
CH1-Fc
NheI:3784


pHIgL5hyg (7.8kb)
NotI 7055
pUC-ori
NotI 753
AscI 918
syn.poly(A)
TOPO1-promoter
CMV enhancer
hE2F1a promoter
TOP1MARII+
Intron
HTLV R-U5'
bAct/bGlo hybrid Intron
HindIII 2324
EcoRI 2318
(Esp3I) 2398
VL
HindIII 5426
Hygromycin-R
WPRE
(Esp3I) 2731
CLambda
TOPO1 polyA
SV40 poly(A)
NheI 3056


[図2]


SphI:11112
pUC ori
syn.poly(A)
SV40 ori
TOP1MARII+
CBX3C-UCOE
CMV enhancer
hE2F1α promoter
zeocin-R
SV40 poly(A)
HTLV R-U5'
WPRE
pTX7z-HIgG1L-#35
(11381 bp)
EF1-intron
SalI:8092
Puro-R
VL
EcoRI:3511
P2A
CL
EGFP
IRES
MluI:7420
VH
IRES
Hinge-Fc
EcoRI:4269


[図3]


3.5
3
2.5
2
1.5
1
0.5
0
Absorbancee at 450nm
1
2
3
4
5
6
7
8
9
Dilution log2


[図4]


(A)
Pancreas
Cancer adjacent pancreas tissue
Cripto-1 #35
negative control
(a)
(b)
(c)
(B)
Thymus gland
Thymus gland carcinoma, Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(C)
Prostate
Adenocarcinoma (Gleason grade:4), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(D)
Stomach
Adjacent normal gastric tissue (chronic atrophic inflammation of gastric body)
Cripto-1 #35
negative control
(a)
(b)
(c)


[図5]


(A)
Stomach
Cancer adjacent gastric tissue (chronic atrophic inflammation with intestinal metaplasia of gastric antrum)
Cripto-1 #35
negative control
(a)
(b)
(c)
(B)
Stomach
Mucous adenocarcinoma(IIA), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(C)
Cervix
Squamous cell carcinoma (IIA, Malignant)
Cripto-1 #35
negative control
(a)
(b)
(c)
(D)
Cervix
Squamous cell carcinoma (IB, Malignant)
Cripto-1 #35
negative control
(a)
(b)
(c)


[図6]


(A)
Cervix
Cancer adjacent cervix tissue (chronic cervicit is with atypical hyperplasia)
Cripto-1 #35
negative control
(a)
(b)
(c)
(B)
Colon
Adenocarcinoma(IIB), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)
(C)
Cervix
Squamous cell carcinoma (IIA, Malignant)
Cripto-1 #35
negative control
(a)
(b)
(c)
(D)
Breast
Invasive ductal carcinoma(IB), Malignant
Cripto-1 #35
negative control
(a)
(b)
(c)

[図7]


3.5
3
2.5
2
1.5
1
0.5
0
U251MG
U251MG-SC1
SOX2
C-MYC
OCT3/4
KLF4
NANOG

[図8]


0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1/1280
1/640
1/320
1/160
1/80
1/ 40
1/20
1/10
1/5